Olutasidenib: from bench to bedside

The discovery of isocitrate dehydrogenase 1 (IDH1) mutations in acute myeloid leukemia (AML) and the resounding success of molecularly targeted therapies in related myeloid malignancies swiftly prompted the development of IDH1(mut) inhibitors. Olutasidenib (formerly known as FT-2102) is an orally ad...

Descripción completa

Detalles Bibliográficos
Autores principales: Venugopal, Sangeetha, Watts, Justin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The American Society of Hematology 2023
Materias:
Review Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10432604/
https://www.ncbi.nlm.nih.gov/pubmed/37196640
http://dx.doi.org/10.1182/bloodadvances.2023009854
Descripción
Sumario:The discovery of isocitrate dehydrogenase 1 (IDH1) mutations in acute myeloid leukemia (AML) and the resounding success of molecularly targeted therapies in related myeloid malignancies swiftly prompted the development of IDH1(mut) inhibitors. Olutasidenib (formerly known as FT-2102) is an orally administered novel IDH1(mut) inhibitor that entered clinical development in 2016, proceeded briskly through the developmental process, and was granted regular approval to treat patients with R/R IDH1(mut) AML on 1 December 2022. Single agent olutasidenib, a potent and selective IDH1(mut) inhibitor, demonstrated highly durable remission rates along with meaningful outcomes, such as transfusion independence, in patients with R/R IDH1(mut) AML. This review will examine the preclinical and clinical development and the positioning of olutasidenib in the IDH1(mut) AML treatment landscape.

Ejemplares similares